This webinar explored a global overview for Liquid Biopsy that covered different topics including clinical utility, the advantages and limitation, issues and emerging opportunities, process / technology and controversies.
Wednesday 28th June 2023 at 3:00pm CET
Click the link below to request access to the recording
- Diaceutics - Welcome & introduction to Diaceutics.
- Dr. Giordano - General overview of Liquid Biopsy & Technologies in Liquid Biopsy
- Dr. B. Bellosillo - Pros, cons and limitations of Liquid Biopsy & Future perspectives in Liquid Biopsy
- All participants - Discussion and questions.
If you enjoyed the first event of the Diaceutics Liquid Biopsy Series, sign up now for the next installment!
Sign up today
Speaker name: Dr. Beatriz Bellosillo
Dr. Bellosillo is the Head of the Molecular Biology Laboratory in the Pathology Department at Hospital del Mar (Barcelona, Spain). She is also Associate Professor at the Pompeu Fabra University (Barcelona). She is a member of different national and international scientific societies. Dr. Bellosillo has a wide experience in molecular biology applied to clinical diagnostics, as well as in translational research, having worked extensively in the area of liquid biopsy in recent years. Also working in the Instituto Hospital del Mar de Investigaciones Médicas (IMIM), she has conducted many research projects in the area of hematology and oncology, in which she has been the principal investigator. She has published more than 200 peer-reviewed publications (with an H-factor of 48) and developed two molecular biomarker related patents that are currently in the commercial operating phase.
Speaker name: Prof. Antonio Giordano
Prof. Giordano is the President and Founder of the Sbarro Health Research Organization (SHRO), which conducts research to diagnose, treat and cure cancer, cardiovascular disease, diabetes, and other chronic illnesses; moreover, he is a Professor of Molecular Biology at Temple University in Philadelphia, USA, and Professor in the Department of Pathology & Oncology at the University of Siena, Italy. In his research throughout the years, Dr. Antonio Giordano identified a tumor suppressor gene, Rb2/p130, that has been found to be active in the lung, endometrial, brain, breast, liver, and ovarian cancers. In 2011, Prof. Giordano and his team uncovered anti-tumor agents that might be effective in the treatment of mesothelioma, cancer caused by prolonged asbestos exposure. Prof. Giordano has published over 600 papers on gene therapy, cell cycle, genetics of cancer, and epidemiology. He is co-author of a book on the use of liquid biopsy: "Liquid Biopsy. New Challenges in the Era of Immunotherapy and Precision Oncology".
Sign up to the full series below!
To be included in all the upcoming LabTalks in the Liquid Biopsy series and receive exclusive access to the recordings of previous Liquid Biopsy LabTalks, sign up here.